Immunotherapy shows promise for metastatic solid tumors, including colon cancer, offering new avenues for effective treatment options.
Early findings from a small clinical trial suggest a promising cellular immunotherapy approach for treating metastatic solid tumors. Researchers genetically engineered normal white blood cells, called lymphocytes, in each patient to produce receptors targeting their specific cancer cells. These initial results, from individuals with metastatic colorectal cancer who had undergone multiple prior treatments, showed that personalized immunotherapy shrank tumors in several patients and prevented regrowth for up to seven months. The findings were published in Nature Medicine (1✔ ✔Trusted Source
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
Go to source).
Cellular Immunotherapy for Solid Cancers
One form of cellular immunotherapy, chimeric antigen receptor (CAR) T-cell therapy, has already been shown to be effective against some blood cancers, and another, called tumor-infiltrating lymphocyte (TIL) therapy, has proven to be effective against metastatic melanoma.‘#Lymphocytes from #coloncancer patients were reengineered to specifically target their cancer cells, resulting in #tumor shrinkage. #immunotherapy’
However, to date, a cellular therapy that’s effective against any other solid cancers has been elusive, according to Steven A. Rosenberg, M.D., Ph.D., of NCI’s Center for Cancer Research (CCR), who co-led the study with Maria Parkhurst, Ph.D., of CCR’s Surgery Branch. “The fact that we can take a growing metastatic solid cancer and get it to regress shows that the new cellular immunotherapy approach has promise,” Dr. Rosenberg said. “However, it’s important to understand that these findings are preliminary and that the approach needs to be further refined and tested in more types of solid cancers.”
The new approach overcomes two challenges in cellular immunotherapy: how to produce large numbers of T cells that can recognize cancer cells specifically, and how to boost the ability of modified T cells to multiply once they’ve been returned to the patient.
For each patient in the study, Dr. Rosenberg and his colleagues collected lymphocytes present in the patient’s tumors. They then used sophisticated molecular characterization techniques to identify and isolate receptors on those lymphocytes, called T-cell receptors, that recognized specific changes in each patient’s tumor. After genetically sequencing those receptors, they then used a retrovirus to insert the genes for the receptor into normal lymphocytes collected from each patient’s circulating blood.
The genetically modified lymphocytes were then multiplied into the hundreds of millions in the laboratory and infused back into the patients, where they expressed the tumor-specific T-cell receptors and continued to multiply.
Advertisement
As part of a larger phase 2 trial, seven patients with metastatic colon cancer were treated with the experimental personalized cellular immunotherapy. All seven received several doses of the immunotherapy drug pembrolizumab before the cell therapy and another immunotherapy drug called IL-2 afterward. Three patients had substantial shrinkage of metastatic tumors in the liver, lung, and lymph nodes that lasted for four to seven months. The median time to disease progression was 4.6 months.
Advertisement
Colon cancer is just one of many solid tumors the researchers are studying. The trial is still ongoing and includes patients with different types of solid cancers.
“It's just the very beginning of converting normal lymphocytes into cells capable of treating the common solid cancers,” Dr. Rosenberg said. “What this study shows is that it's possible. Once you know it’s possible, you work to improve it.”
Reference:
- Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - (https://www.nature.com/articles/s41591-024-03109-0)
Source-Eurekalert